Management of the australianclinicaltrials.gov.au website has been transferred from NHMRC to the Commonwealth Department of Health. Disruption to site users as a consequence of this change should be minimal. Users should note that email notifications coming from the website will come from australianclinicaltrials@health.gov.au from Friday the 8th of April 2022. Any user experiencing difficulty as a result of this change should direct enquiries to australianclinicaltrials@health.gov.au for assistance.
Broad Health Condition Cancer
Specific Health ConditionMyeloma
Recruitment statusRecruiting
Recruitment Details
Recruitment State
NSW,TAS,WA,VIC
Hospital
The Alfred - Prahran
St Vincent's Hospital (Melbourne) Ltd - Fitzroy
Epworth Freemasons (Clarendon Street) - East Melbourne
Royal Hobart Hospital - Hobart
Flinders Medical Centre - Bedford Park
Fiona Stanley Hospital - Murdoch
St George Hospital - Kogarah
Border Medical Oncology - Albury
Concord Repatriation Hospital - Concord
Calvary Mater Newcastle - Waratah
Postcode
3004 - Prahran
3065 - Fitzroy
3002 - East Melbourne
7000 - Hobart
5042 - Bedford Park
6150 - Murdoch
2217 - Kogarah
2640 - Albury
2139 - Concord
2298 - Waratah
Anticipated date of first participant enrolment25/03/2019
Anticipated date of last participant enrolment25/03/2019
Has the study received ethics approval?Approved
Trial summary
The purpose of this study is to determine whether Isatuximab (a new drug), when combined with chemotherapy, improves response to treatment. Who is it for? You may be eligible to participate in this trial if you are aged 18 years or over, have been newly diagnosed with multiple myeloma and are not a candidate for high dose chemotherapy and autologous stem cell transplant. Study Details Eligible participants will receive lenalidomide and dexamethasone (Ld). Participants who have inadequate response to upfront treatment with Ld, will have the addition of Isatuximab. Treatment (each cycle is 28 days) will be given until disease progression, unacceptable toxicity, or withdrawal of consent. Participants will be required to have blood samples taken at the beginning of each cycle along with a medical exam in order for researchers to monitor whether the treatment is safe and whether it is effectively treating the myeloma. It is hoped that the findings of this trial will establish the benefits of Isatuximab in combination with Ld for the treatment of multiple myeloma patients early in the course of their disease.
Key inclusion criteria
1. Patient has voluntarily agreed and has given written informed consent to both the main study and the correlative study. 2. Male and Female patients, 18 years or older of age 3. Diagnosed with MM (diagnosis of MM as per IMWG) 4. Measurable M-component in serum or urine, In patients with no detectable M-component, an abnormal FLC ratio on the serum FLC assay 5. No prior therapies (except radiotherapy or short course of corticosteroids equivalent to dexamethasone 160mg in the last 28 days) or have started Ld as first line therapy but not completed cycle 4 of Ld and whose response status is SD or better 6. ECOG performance status 0-2 7. Adequate liver function (ALT, AST and GGT less than or equal to 2.5 x institutional upper limit of normal; GGT less than or equal to'1.5 x institutional upper limit of normal ) 8. CrCl >15ml/min 9. Hb greater than or equal to 80g/L, Platelet count greater than or equal to 75 x 10^9/L, absolute neutrophil count greater than or equal to 1.0 x 10^9/L 10. No contraindication to the use of any of the study drugs 11. Life expectancy of greater than 6 months 12. Patients must be registered on and abide by the Celgene i-access Risk Management Program before receiving first dose of lenalidomide (www.iaccesscelgene.com)
Minimum age18 Years
GenderBoth males and females
Can Healthy volunteers participate?No
Key exclusion criteria
1. Primary amyloidosis 2. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements 3.Pregnant or lactating women. 4. Known acquired immunodeficiency syndrome (AIDS-related illness) or known HIV disease requiring antiviral treatment, or active hepatitis A, B, or C infection
Sponsor Primary Sponsor Type: Other Collaborative groups
Primary Sponsor Name: Australasian Myeloma Research Consortium
Primary Sponsor Address: 55 Commercial Rd, Melbourne VIC 3004
Primary Sponsor Country: Australia
Trial IDACTRN12619000362190
Contact person for information and recruitmentMiss
Flora Yuen
Alfred Hospital
55 Commercial Road, Melbourne VIC 3004
+61390765407flora.yuen@alfred.org.au
Australia